ClinicalTrials.gg
TerminatedNCT05833321SARCO-GYNUpdated Oct 8, 2026

Prospective Study of Detection of Sarcopenia in Clinical Practice for Patient With Ovarian or Endometrial Cancer

An interventional study of Sarcopenia diagnostic test in Ovarian Neoplasms and Sarcopenia, sponsored by Centre Hospitalier Metropole Savoie. Terminated at 1 site in France. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-08.

Sponsored by Centre Hospitalier Metropole Savoie · Not applicable, Interventional, and Diagnostic

How we know

Why this study was terminated
recruitement failure

From the registry’s dates

  • Registered 4 months after the study started (first participant enrolled Nov 2022, registered Apr 2023).
Updated Oct 8, 2026Now TerminatedPrimary completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
6
Allocation
Not applicable
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 291 studies in Ovarian Neoplasms with a site in France — 63 open to participants now, 103 under way, 25 of them phase 3. Ovarian Neoplasms · France.

Enrollment
240th of 245
6 · median 201
Started
2022
with 14 others
No phase
53 of 291
13 open now
Registered
238th of 291
by date

Among the 291 studies in Ovarian Neoplasms with a site in France, this one is the 240th largest by enrollment of the 245 interventional ones that give a count, is one of 15 that started in 2022, is one of 53 with no phase, and was the 238th registered.

Ovarian Neoplasms

3,390 studies on the registry are indexed under Ovarian Neoplasms; 790 are open to participants now.

Browse Ovarian Neoplasms studies →

Open to participants now

63 of the 291 studies in Ovarian Neoplasms with a site in France are open now. Recruiting first, the newest first:

58 more — sign in →

All 63 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 603 Ovarian Neoplasms studies recruiting now, 438 (73%) set no upper age limit and 108 (18%) stop at 75 or younger; 39 take children under 18; 46 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 291 studies in Ovarian Neoplasms with a site in France, or all of them as a file.
02

Study summary

Prospective monocentric study, non-randomized of the detection of sarcopenia in clinical practice in patients with ovarian or endometrial cancer requiring systemic oncological treatment.

main question : Identify the criteria correlated with the presence of sarcopenia (defined by the measurement of the IMS by the CT-X method in L3) among the impedancemetry and the HAS malnutrition criteria.

Data collection will be done at 6 months, 12 months after the date of inclusion.

Read the detailed description

Primary objective:Identify the criteria correlated to the presence of sarcopenia (defined by the measurement of the IMS by the CT-X method in L3) among the impedancemetry and the HAS malnutrition criteria

Main judgment criteria : Comparison between the groups of patients with sarcopenia (Morphometric measurement of the musculoskeletal surface index \<39cm²/m² in L3 cross section) and without sarcopenia of the different evaluation criteria:

  • Impedancemetry values:: muscle mass index in kg/m2 (IMS), fat-free mass in kg/m2 and metabolic activity index (phase angle)
  • Percentage of weight loss
  • BMI \< 18.5 kg/m2
  • Quantified reduction in muscle mass and/or function for patients \< 70 years old
  • Quantified reduction in muscle mass and function for patients > 70 years old
  • Physical tests: walking speed and "hand grip" dynamometer secondary objectives:- Proposal of a composite score for the detection of sarcopenia usable in clinical routine
  • Evaluation of nutritional intake
  • Evaluation of the severity of undernutrition
  • Verification of a correlation between the sarcopenia indices of ovarian and endometrial cancer
  • Evaluate tolerance profiles to systemic treatments with regard to sarcopenia figures
  • Assess the relationship between PFS, OS and sarcopenia index in cancer diagnosis secondary judgment criteria :
  • Statistical analysis of sarcopenia and undernutrition data
  • Quantification of ingestates (SEFI scale) +/- intake of oral nutritional supplement
  • Serological tests: NFS, CRP and Albuminemia
  • Comparison of sarcopenia index figures between ovarian and endometrial cancer
  • Collection of the grades of toxicities and adverse events to systemic treatments in parallel with the measurement of sarcopenia.
  • Correlation between progression-free survival, death and sarcopenia index at cancer diagnosis
03

Conditions studied

  • Ovarian Neoplasms
  • Sarcopenia
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients at least 18 years old
  • Patient presenting with a diagnosis of cancer of ovarian origin with an indication for chemotherapy
  • Patient with a diagnosis of endometrial cancer with an indication for chemotherapy
  • Patient with no diagnosis of other types of cancer in the previous five years
  • Collection of consent
  • Patient affiliated to a Social Security scheme

Exclusion criteria

Exclusion Criteria:

  • Patient with cancer of ovarian origin not requiring chemotherapy treatment
  • Patient with endometrial cancer not requiring chemotherapy treatment
  • Discovery of an intercurrent cancer other than skin or cervix cancers.
  • Patient wearing a Pace maker
05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
6 participants (actual)

Study arms

  • Experimental
    Interventionnal

    "Hand Grip" Dynamometer Walk test SEFI Nutritional Intake Assessment Questionnaire

    Diagnostic Test: Sarcopenia diagnostic test

Interventions

  • Diagnostic testSarcopenia diagnostic test

    measurement of impedance and physical tests ("hand grip" dynamometer, walking test), SEFI nutritional intake questionnaire

06

What researchers measure

Primary outcomes

  1. clinical screening for sarcopenia

    Identify the criteria correlated with the presence of sarcopenia (defined by the measurement of the IMS by the CT-X method in L3) among the impedancemetry and the HAS malnutrition criteria.

    Time frame: 36 month

  2. Proposal of a composite score for the detection of sarcopenia usable in clinical routine

    Statistical analysis of sarcopenia and undernutrition data

    Time frame: 36 month

07

Study locations

1 site
  • Centre Hospitalier Metropole Savoie
    Chambéry, Savoie 73011, France
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Ran from Nov 2022 to primary completion in Aug 2024, 20 months.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 8, 2026: primary completion Oct 2025 → Aug 2024 and completion Oct 2026 → Aug 2024.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Apr 17, 2023
First posted
Apr 27, 2023
StartActual
Nov 20, 2022
Primary completionActual
Aug 1, 2024was Oct 2025
CompletionActual
Aug 1, 2024was Oct 2026
Last update
Oct 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Terminated recruitement failure
changed Oct 8, 2026
Primary completion
Oct 2025→Aug 1, 2024 (actual)
Oct 8, 2026
Study completion
Oct 2026→Aug 1, 2024 (actual)
Oct 8, 2026
Enrollment
75 (estimated)→6 (actual)
Oct 8, 2026
Show all 1 update
  1. Oct 8, 2026
    Recruiting→Terminated
    Why stopped recruitement failure
    Primary completion Oct 2025→Aug 1, 2024 (now actual)
    Study completion Oct 2026→Aug 1, 2024 (now actual)
    Enrollment 75 (estimated)→6 (actual)
    + 5 other changes: index terms, identifiers, verification date, contact details and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05833321
Lead sponsor
Centre Hospitalier Metropole Savoie
Responsible party
Sponsor
First posted
Apr 27, 2023
Start date
Nov 20, 2022
Primary completion
Aug 1, 2024
Completion
Aug 1, 2024
Last update
Oct 8, 2026

Study contacts

fillon aurélie
principal investigator · Centre Hospitalier Metropole Savoie

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Dec 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion